Results 91 to 100 of about 23,130 (165)

FRONTIER-3: a randomised phase 2a study to investigate tozorakimab, an anti-interleukin-33 monoclonal antibody, in early-onset asthma. [PDF]

ERJ Open Res
Corren J, Reid F, Moate R, Jimenez E, Sadiq MW, Williams A, Rytelewski M, Cameron-Christie S, Muthas D, Georgi B, Brooks D, Lindqvist E, Kell C, Platt A, Belvisi MG, Pandya H.   +15 more
europepmc   +1 more source

Prognostic Value of Impaired Spirometry in Patients with Myocardial Infarction: A Longitudinal Study of Two European Cohorts. [PDF]

Int J Chron Obstruct Pulmon Dis
Sundh J, Parker WAE, Oldgren J, Andell P, Reitan C, Jernberg T, Hofmann R, Mohammad MA, Erlinge D, Åkerblom A, Sederholm Lawesson S, Konstantinidis KV, Lindbäck J, Janson C, Björkenheim A, Elamin N, McMellon H, Moyle B, Patel M, El Khoury J, Surujbally R, James S, Storey RF.   +22 more
europepmc   +1 more source

IMM2510, a novel anti-PD-L1/VEGF bispecific antibody for cancer immunotherapy. [PDF]

Antib Ther
Chen D, Wu Z, Zhao X, Bhatt RS, Yang Y, Zhu W, Tang H, Wang K, Guo C, Liu D, Yang C, Guo H, Bai X, Zhang R, Li S, Tian W.   +15 more
europepmc   +1 more source

Efficacy and safety of CBL-514 for Dercum disease lipomas: A randomized phase 2a study. [PDF]

JAAD Int
Herbst KL, Ling YF, Sheu AY, Schlessinger DI, Wu SY.   +4 more
europepmc   +1 more source

Erdafitinib in Patients With Advanced Solid Tumors With <i>FGFR</i> Alterations (RAGNAR): Results of Tumor-Specific Analyses and Secondary Cohorts. [PDF]

JCO Precis Oncol
Carranza O, Pant S, Schuler M, Witt O, Geoerger B, Loriot Y, Farouk Sait S, Arnold D, Dal Molin GZ, Lugowska I, Winter H, Baldini C, Corassa M, Thomas S, Crow L, Xia Y, Triantos S, Sweiti H, Reardon DA.   +18 more
europepmc   +1 more source

Trends in the management and coding of chronic kidney disease in Spain: cross-sectional analyses of real-life data with a 5-year interval. [PDF]

Clin Kidney J
Santamaría R, Pimentel B, Palacios B, Hernández I, Escobar C, Gorostidi M, Cebrian A, Alcázar R.   +7 more
europepmc   +1 more source

Elarekibep, an inhaled anti-IL-4 receptor alpha Anticalin, in moderate-to-severe asthma: a randomized, placebo-controlled phase 2a study (APATURA). [PDF]

Respir Res
Hugo T, Harper AR, Leander J, Gardiner P, Palmér R, Lundin P, Bock D, Zhou XH, Bondarenko I, Burns S, Wiegert E, Fitzgerald MF, Close DR, Keeling DJ, Pandya H, Belvisi MG, O'Byrne PM.   +16 more
europepmc   +1 more source

Real-world experience of anifrolumab treatment in patients with moderate-to-severe SLE: a retrospective study of patients in early access programmes. [PDF]

Lupus Sci Med
Vital EM, Chasset F, Faria R, Carter LM, Kielar D, Chen SY, Chen S, Nåtman J, Waratani M.   +8 more
europepmc   +1 more source

Bioequivalence of budesonide/glycopyrrolate/formoterol fumarate with a next-generation propellant versus hydrofluoroalkane-134a in healthy adults: phase I, randomized, double-blind, single-dose, partial-replicate, three-way cross-over lung exposure and total systemic exposure studies. [PDF]

Ther Adv Respir Dis
Bednarczyk A, Aurivillius M, Jassal M, Shah M, Raphiou I, Petullo D, Xu J, Heijer M, Sychowicz K, Collison K, Silva C, Reddy J, Han D, Goldwater R, Gillen M, Patel M.   +15 more
europepmc   +1 more source

Biopharmaceutic

Journal of Pharmacy and Pharmacology, 2006
openaire   +1 more source